Supernus Shares Tumble 20% After Depression Study Misses Endpoint
Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression.
The stock was down 20% in premarket trading Wednesday. This biopharmaceutical company's stock is up 9.9% this year.
Supernus said results from the study didn't demonstrate statistically significant improvement on the primary endpoint of reduction in depressive symptoms compared to a placebo. The company added SPN-820 was well-tolerated with few adverse events.
President and Chief Executive Officer Jack Khattar said Supernus will continue to analyze data from the study and discuss the program's future with its development partner Navitor Pharmaceuticals.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。
熱議股票
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10